View Older Stories View More Recent Stories
-
H.C. Wainwright Reiterates Buy Rating on ORIC Pharmaceuticals (ORIC)
-
Wolfe Research Reiterates Peerperform Rating on ORIC Pharmaceuticals (ORIC)
-
ORIC Pharmaceuticals (ORIC) Reiterated at Overweight by Cantor Fitzgerald
-
Upcoming prostate cancer data could drive shares of this pharma company
-
JPMorgan on ORIC Pharmaceuticals (ORIC): 'We Are Buyers On Weakness'
-
Cantor Fitzgerald Reiterates Overweight Rating on ORIC Pharmaceuticals (ORIC): "today’s move seems like an over-reaction"
-
Jones Trading on ORIC Pharmaceuticals (ORIC): "We see pressure" following Ipsen's Tazverik withdrawal
-
Wolfe on ORIC Pharma (ORIC) Amid 12% Decline: 'Net net, we'd frame the newsflow as mixed'
-
ORIC Pharmaceuticals (ORIC) PT Raised to $25 at H.C. Wainwright
-
Oppenheimer Reiterates Outperform Rating on ORIC Pharmaceuticals (ORIC)
-
ORIC Pharmaceuticals, Inc. (ORIC) Tops Q4 EPS by 7c
-
H.C. Wainwright Reiterates Buy Rating on ORIC Pharmaceuticals (ORIC)
-
ORIC Pharmaceuticals raises $244 million, extends cash runway to 2028
-
Piper Sandler Starts ORIC Pharmaceuticals (ORIC) at Overweight
-
Jefferies lists 5 biotech M&A candidates for 2026
-
This SMID biotech stock is on JPMorgan's 'Analyst Focus List'
-
ORIC Pharmaceuticals (ORIC) PT Raised to $25 at Wells Fargo
-
ORIC Pharmaceuticals reports 35% response rate for lung cancer drug
-
Goldman Sachs Starts ORIC Pharmaceuticals (ORIC) at Early-Stage Biotech, 'Potential for differentiated approach in prostate cancer'
-
Evercore ISI Starts ORIC Pharmaceuticals (ORIC) at Outperform
-
Wolfe Research Starts ORIC Pharmaceuticals (ORIC) at Peerperform
-
ORIC Pharmaceuticals, Inc. (ORIC) Tops Q3 EPS by 7c
-
ORIC Pharmaceuticals publishes enozertinib research in Cancer Research
-
Cantor Fitzgerald Reiterates Overweight Rating on ORIC Pharmaceuticals (ORIC)
-
Guggenheim Assumes ORIC Pharmaceuticals (ORIC) at Buy
-
ORIC Pharmaceuticals names Kevin Brodbeck as chief technical officer
-
ORIC Pharmaceuticals (ORIC) PT Raised to $23 at Jefferies
-
ORIC Pharmaceuticals, Inc. (ORIC) Misses Q2 EPS by 3c
-
Ladenburg Thalmann Starts ORIC Pharmaceuticals (ORIC) at Buy
-
H.C. Wainwright Reiterates Buy Rating on ORIC Pharmaceuticals (ORIC)
-
Cantor Fitzgerald Reiterates Overweight Rating on ORIC Pharmaceuticals (ORIC)
-
Cantor Fitzgerald on ORIC Pharmaceuticals (ORIC): 'Solid Update in Prostate Cancer for ORIC-944'
-
ORIC Pharmaceuticals Inc. (ORIC) Announces $125 Million Private Placement at $6.50/sh
-
ORIC Pharmaceuticals Inc. (ORIC) Shares Continue Strength Follow Y'Day Sell side Comments, +6pct
-
JPMorgan on ORIC Pharamceuticals (ORIC): 'Top Pick', 'ORIC shares should be ~2-4X current levels', PT $20
-
Cantor Fitzgerald Reiterates Overweight Rating on ORIC Pharamceuticals (ORIC)
-
ORIC Pharamceuticals (ORIC) PT Raised to $22 at H.C. Wainwright
-
ORIC Pharmaceuticals, Inc. (ORIC) Tops Q1 EPS by 9c
-
ORIC Pharmaceuticals Inc. (ORIC) Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer
-
ORIC Pharmaceuticals announces inducement grants to three employees
-
Stifel Reiterates Buy Rating on ORIC Pharamceuticals (ORIC)
-
H.C. Wainwright Reiterates Buy Rating on ORIC Pharamceuticals (ORIC)
-
Jones Trading Reiterates Buy Rating on ORIC Pharamceuticals (ORIC)
-
Cantor Fitzgerald Reiterates Overweight Rating on ORIC Pharamceuticals (ORIC) Following Possible ASCO-GU Feb 13 News Title Leak
-
Cantor Says Buy ORIC Pharmaceuticals Inc. (ORIC) Shares On Possible Mevro Data Leak
-
Cantor Fitzgerald Reiterates Overweight Rating on ORIC Pharamceuticals (ORIC)
-
Citi Opens 30-Day Upside Catalyst Call on ORIC Pharamceuticals (ORIC)
-
ORIC Pharmaceuticals Inc. (ORIC) Provides Early Phase 1b Combination Data for ORIC-944
-
ORIC Pharmaceuticals, Inc. (ORIC) Misses Q3 EPS by 1c
-
Jones Trading Starts ORIC Pharamceuticals (ORIC) at Buy
